Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 5/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 10/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 10/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3841812 | 1.00 | CAPN1 (0.44) | CAPN1TAS1R3TAS1R1TYRPOLB | |
| SCHEMBL3840752 | 1.00 | CAPN1 (0.44) | CAPN1TAS1R3TAS1R1TYRPOLB | |
| SCHEMBL3842586 | 1.00 | CAPN1 (0.44) | CAPN1TAS1R3TAS1R1TYRPOLB | |
| SCHEMBL3840104 | 0.96 | CAPN1 (0.41) | CAPN1TAS1R3TAS1R1TYRPOLB | |
| SCHEMBL16214295 | 0.87 | CAPN1 (0.38) | CAPN1 | |
| SCHEMBL4391955 | 0.85 | TYR (0.37) | CAPN1TAS1R3TAS1R1TYRPOLB | |
| SCHEMBL4541619 | 0.83 | CTSK (0.37) | TYRPOLBCTSK | |
| SCHEMBL5880046 | 0.83 | TAS1R3 (0.39) | TAS1R3TAS1R1TYRCTSK | |
| SCHEMBL12990568 | 0.82 | HPGD (0.35) | CAPN1POLB | |
| SCHEMBL10600585 | 0.81 | ALDH1A1 (0.49) | TAS1R3TAS1R1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3466421-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | Osaka City University (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-2647386-B1 | LISSENCEPHALY THERAPEUTIC AGENT | UNIV OSAKA CITY (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-9539298-B2 | Lissencephaly therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20160250276-A1 | LISSENCEPHALY THERAPEUTIC AGENT | OSAKA CITY UNIVERSITY (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371359-B2 | Lissencephaly therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2016-06-21 | — | — | US | disclosed |
| EP-2647386-A1 | LISSENCEPHALY THERAPEUTIC AGENT | Osaka City University (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130244945-A1 | LISSENCEPHALY THERAPEUTIC AGENT | OSAKA CITY UNIVERSITY | 2013-09-19 | — | — | US | disclosed |
| EP-1692098-B1 | ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF | SENJU PHARMA CO (JP) | 2009-10-28 | — | — | EP | disclosed |
| US-7491705-B2 | Alpha-ketoamide derivative, and production method and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20070004643-A1 | Alpha-ketoamide derivative, and production method and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244945-A1 | LISSENCEPHALY THERAPEUTIC AGENT | ASPH, DCX, ERH | CAPN1 2767/4885TAS1R3 2530/4885TAS1R1 2102/4885 |
| US-20070004643-A1 | Alpha-ketoamide derivative, and production method and use thereof | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885TAS1R3 4142/4885TAS1R1 3946/4885 |
| US-20160250276-A1 | LISSENCEPHALY THERAPEUTIC AGENT | ASPH, DCX, P4HA1 | CAPN1 2695/4885TAS1R3 2511/4885TAS1R1 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.